4. Effects of keloid properties on treatment efficacy 106 Total no. keloid patients: 78. Bijlard et al., 2018 History of recurrence A: IL cryotherapy + excision + IL TCA B: IL cryotherapy + excision + brachytherapy - History of recurrence: IL cryotherapy resulted in 40% reduction in scar volume in treatment naïve keloids, compared to 1% reduction in recalcitrant keloids. Keloid volume Primary keloid: excision with TCA (n=5), IL cryotherapy (n=5). Recalcitrant keloid: excision with brachytherapy (n=7), IL cryotherapy (n=9). Total no. keloid patients: 26. Davison et al., 2006 Ethnicity, location (Postoperative) A: IL interferon alpha-2b; B: IL TCA - Ethnicity and location: NS. No. recurrences Ethnicity: African American (n=21), Caucasian (n=13), Hispanic (n=4), Asian (n=1). Location: ear (n=10), face/scalp (n=8), chest (n=7), extremity (n=6), abdomen (n=4), neck (n=4). Total no. keloid patients: 34. Hewedy et al., 2022 (10) Duration A: IL TCA + PRP; B: IL TCA - Duration: NS. VSS score Mean duration (months): 15.8 (n=20); 16.5. (n=20). Total no. keloid patients: 40. Ismail et al., 2021 Duration, size A: IL BTX-A; B: IL 5-FU - Size: NS in groups receiving BTX-A. However, small, and medium lesions in the group receiving IL 5-FU showed a significantly better response than larger lesions. - Duration: NS. Keloid height Duration: ≤ 2 years (n=43), > 2 years (n=26). Size: Small <1 cm3 (n=43), medium 1-5 cm3 (n=20), large >5 cm3 (n=6). Total no. keloid patients: 50. Khan et al., 2019 Baseline POSAS, duration skin type A: IL bleomycin; B: IL TCA - Fitzpatrick skin type, keloid duration and baseline POSAS score: NS. POSAS score Mean duration (months): 4 (n=164). Skin type: type 2 (n=31), type 3 (n=63), type 4 (n=54), type 5 (n=16). Mean POSAS Baseline: 90 (n=82), 91 (n=82). Total no. keloid patients: 164. Manzoor et al., 2022 Duration A: IL 5-FU; B: IL TCA alone, C: IL TCA + 5-FU -Duration: NS. VSS score Mean duration (months): 5.03 (n=30), 6.30 (n=30), 5.27 (n=30).
RkJQdWJsaXNoZXIy MTk4NDMw